Influence of COMT inhibition on levodopa pharmacology and therapy

@article{Goetz1998InfluenceOC,
  title={Influence of COMT inhibition on levodopa pharmacology and therapy},
  author={Christopher G Goetz},
  journal={Neurology},
  year={1998},
  volume={50},
  pages={S26 - S30}
}
  • C. Goetz
  • Published 1998
  • Psychology, Medicine
  • Neurology
Catechol O-methyltransferase (COMT) is an important enzyme that is linked directly to therapy with levodopa. Considering the demonstrated mechanism of action and pharmacologic profiles of COMT inhibitors, it is reasonable to hypothesize that these agents would improve the disability associated with Parkinson's disease. Two basic classes of COMT inhibitors are being studied in patients with PD: those that act exclusively extracerebrally or peripherally (e.g., entacapone) and those that cross the… Expand
Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
  • J. Najib
  • Medicine
  • Clinical therapeutics
  • 2001
TLDR
In clinical trials, adjuvant treatment with entacapone appeared to be an effective and well-tolerated therapeutic strategy in patients with Parkinson's disease who experience fluctuations in the response to levodopa therapy. Expand
Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease.
TLDR
Parkinson's disease is the most common neurodegenerative disease in which the chemical pathology is known and effective symptomatic treatment, levodopa, is available, but by 5 years after the initiation of treatment, over two thirds of patients experience motor fluctuations beginning initially with a "wearing- off" effect followed by more complex fluctuations including dyskinesias and "on-off" responses. Expand
Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson’s disease
TLDR
Comparisons of the effects of a 3-month therapy with catechol-O-methyltransferase (COMT) inhibitors and entacapone on L-DOPA metabolism in parkinsonian patients with motor fluctuations confirm the different profiles of activity of the two drugs. Expand
Catechol-O-methyltransferase inhibition attenuates levodopa toxicity in mesencephalic dopamine neurons.
TLDR
It is demonstrated that COMT inhibition attenuates L-dopa toxicity toward DA neurons in vitro, but probably not by preventing 3-O-methyldopa production or cellular S-adenosyl-L-methionine depletion. Expand
Pharmacokinetic-Pharmacodynamic Modeling of Levodopa in Patients With Advanced Parkinson Disease
TLDR
The motor complications during long treatment therapy in patients with advanced PD especially with stage 3 Hoehn and Yahr scale were correlated to the higher plasma concentrations of l-dopa, and pk/pd analysis may be helpful for monitoring the efficiency of therapeutic strategy applied in PD patients. Expand
Advances in the pharmacological management of Parkinson disease.
  • E. Tolosa
  • Medicine
  • Journal of neural transmission. Supplementum
  • 2003
TLDR
Preliminary reports suggest that cholinesterase inhibitors, such as rivastigmine, can be usefull in the management of cognitive impairment in PD, one of the most difficult clinical problems encountered in the Management of this neurodegenerative disorder. Expand
Dopaminergic neurotoxicity of homocysteine and its derivatives in primary mesencephalic cultures.
TLDR
The results do not demonstrate relevant dopaminergic toxicity of HC in vitro, and therefore HC is most likely not involved in the pathogenesis of PD or in accelerating the progression of PD by levodopa. Expand
Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration
Levodopa (L-DOPA) is widely used for symptomatic management in Parkinson's disease. We recently showed that (-)-epigallocatechin-3-gallate, a tea polyphenol, not only inhibits L-DOPA methylation, butExpand
Switch-Over from Tolcapone to Entacapone in Severe Parkinson’s Disease Patients
TLDR
Forty patients affected by severe Parkinson’s disease were treated with tolcapone as an adjunctive therapy to L-DOPA, for 3–7 months, until this drug was discontinued because of side-effects or because of mandatory indications of the European drugs authority. Expand
Therapeutic and Diagnostic Agents for Parkinson’s Disease
This chapter considers the biology and medical chemistry-based treatment of Parkinson’s disease, the second most common of the major neurodegenerative neuropsychiatric disorders. It surveys basicExpand
...
1
2
3
...

References

SHOWING 1-10 OF 28 REFERENCES
Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.
TLDR
Entacapone (OR-611), a novel COMT inhibitor, was assessed in 12 patients with Parkinson's disease and motor fluctuations in a randomised, double-blind, cross-over, single dose study. Expand
Catechol‐O‐methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients
TLDR
Multiple daily dosing with tolcapone would be expected to safely reduce the wearing-off phenomenon associated with levodopdcarbidopa therapy, which frequently complicates levodopa therapy of Parkinson's disease. Expand
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers.
TLDR
Entacapone improves the pharmacokinetic profile oflevodopa when used in combination with a CR levodopa preparation, as it does with a standard levodOPA preparation. Expand
General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase.
TLDR
In the first clinical studies in patients with Parkinson's disease, both entacapone and tolcapone potentiate and prolong the therapeutic effect of L-dopa, thus improving its bioavailability and brain penetration and potentiating its behavioural effects. Expand
The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers.
TLDR
The in vivo biochemical effects of entacapone indicate that it is an orally active COMT inhibitor and that it may improve the therapeutic efficacy of levodopa in Parkinson's disease. Expand
Effect of peripheral catechol‐O‐methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients
TLDR
It is concluded that inhibition of COMT by entacapone increases the plasma half-life of levodopa and augments the antiparkinsonian effects of single and repeated doses of Levodopa. Expand
Improved Therapy of Parkinson's Disease with Tolcapone, a Central and Peripheral COMT Inhibitor with an S‐Adenosyl‐L‐Methionine‐Sparing Effect
TLDR
The results support the concept that in the therapy of Parkinson's disease (PD), coadministration of Madopar or Sinemet with tolcapone will improve the beneficial effect of levodopa by increasing its bioavailability to the CNS. Expand
Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues.
TLDR
Ro 40-7592, combined with peripheral decarboxylase inhibitors and L-DOPA (as in Madopar and Sinemet), will offer substantial advantages in the therapy of Parkinson's disease, i.e. enhanced bioavailability and prolonged plasma half-life of L- DOPA, pronounced DOPA sparing effect and blockade of 3-OMD formation. Expand
Tolcapone: a potential new antidepressant detected in a novel animal model of depression
TLDR
The results suggest that selective, reversible COMT inhibitors such as tolcapone may offer an innovative approach to the treatment of depression, in addition to their potential therapeutic use in Parkinson's disease. Expand
3‐O‐methyldopa administration does not alter fluorodopa transport into the brain
TLDR
Results do not support the hypothesis that transport of L‐dopa into the brain is inhibited by 3OMd to cause the declining response seen in patients with advanced Parkinson's disease and 6‐FD positron emission tomographic studies in parkinsonian patients will not be altered by 3O‐methyldopa present in the blood in those patients taking L‐ dopa preparations. Expand
...
1
2
3
...